ReviewInternational journal of molecular sciences2016
Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs).
Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Targeting Prostate Cancer Cells Using Anti-Sortilin and Anti-Syndecan-1 Antibody Drug Conjugates.International journal of molecular sciences · 2025Article
- Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates.Discover nano · 2025Review
- Method for Screening Sodium Cyanoborohydride for Free Cyanide Content and Its Impact on Bioconjugation Chemistry.Bioconjugate chemistry · 2025Article
- Resistance to antibody-drug conjugates: A review.Acta pharmaceutica Sinica. B · 2025Review
- Emerging approaches for T cell-stimulating platform development.Cell systems · 2024Review
- Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024Review
- Single-Domain Antibodies as Antibody-Drug Conjugates: From Promise to Practice-A Systematic Review.Cancers · 2024Review
- Penetration of Nanobody-Dextran Polymer Conjugates through Tumor Spheroids.Pharmaceutics · 2023Article
- Genetic Code Expansion for Site-Specific Labeling of Antibodies with Radioisotopes.ACS chemical biology · 2023Article
- A magnetic antibody-conjugated nano-system for selective delivery of Ca(OH)Communications biology · 2022Article
- DNA sequence-selective G-A cross-linking ADC payloads for use in solid tumour therapies.Communications biology · 2022Article
- Drug Conjugation via Maleimide-Thiol Chemistry Does Not Affect Targeting Properties of Cysteine-Containing Anti-FGFR1 Peptibodies.Molecular pharmaceutics · 2022Article
- Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry.RSC chemical biology · 2022Review
- The Use of Antibody-Antibiotic Conjugates to Fight Bacterial Infections.Frontiers in microbiology · 2022Review
- Stepping forward in antibody-drug conjugate development.Pharmacology & therapeutics · 2022Review
- Conjugation of a Blood Brain Barrier Peptide Shuttle to an Fc Domain for Brain Delivery of Therapeutic Biomolecules.ACS medicinal chemistry letters · 2021Article
- Efficient Labeling of Native Human IgG by Proximity-Based Sortase-Mediated Isopeptide Ligation.Bioconjugate chemistry · 2021Article
- BFMolecules (Basel, Switzerland) · 2021Article
- Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy.Frontiers in cell and developmental biology · 2021Review
- Development of Anti-ImmunoTargets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates (ADCs) have become a promising targeted therapy strategy that combines the specificity, favorable pharmacokinetics and biodistributions of antibodies with the destructive potential of highly potent drugs. One of the biggest challenges in the development of ADCs is the application of suitable linkers for conjugating drugs to antibodies. Recently, the design and synthesis of linkers are making great progress. In this review, we present the methods that are currently used to synthesize antibody-drug conjugates by using thiols, amines, alcohols, aldehydes and azides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.